Roya Dehquan Dehnavi; Seyed Abdolhamid Angaji; Behnaz Beikzadeh; Hengameh Alibeik; Raheleh Roudi; Behzad Narouie
Abstract
Prostate cancer is the second most prevalent malignancy in men and the fifth leading cause of death worldwide. It is the second most common urinary tract cancer among Iranian men. The aim of this study was to investigate the association between rs10090154, located on the 8q24 locus, and rs1691053 on ...
Read More
Prostate cancer is the second most prevalent malignancy in men and the fifth leading cause of death worldwide. It is the second most common urinary tract cancer among Iranian men. The aim of this study was to investigate the association between rs10090154, located on the 8q24 locus, and rs1691053 on chromosome 5p15.31, with prostate adenocarcinoma and PSA levels. This study also aimed to identify the potential of these genetic markers as screening factors. This case-control study included 79 patients with prostate adenocarcinoma aged between 48 to 86 years, as well as 98 patients with benign prostatic hyperplasia aged between 47 to 81 years. The Tetra-primer ARMS-PCR method was applied to determine the genotype of each participant. In this study, no significant differences in genotypic distribution between the prostate adenocarcinoma and control groups were discovered for rs10090154 (P-value = 0.608) and rs1691053 (P-value = 0.102) polymorphisms. Moreover, for the study of the additive genetics model of the rs10090154 polymorphism, with the TT genotype as the reference, the CC genotype with P-value = 1 and OR {95%CI} = 0.750, {0.039-14.576} and CT genotype with P-value = 0.324 and OR {95%CI} = 0.577, {0.191-1.739}, were not associated. Correspondingly, for rs1691053, with the CC genotype as the reference, the CT genotype with P-value = 0.176 and OR {95%CI}= 0.196, {0.022-1.793}, and the TT genotype with P-value= 0.464, OR{95%CI}= 0.125, {0.005-3.225}, were not associated. These findings suggest that rs10090154 and rs1691053 may not be associated with prostate cancer among Iranians. However, further research with larger sample sizes and investigation of various Iranian subpopulations are needed to confirm these results.
Setare Kakavand; Seyed Abdolhamid Angaji; Behnaz Beikzadeh; Raheleh Roudi; Behzad Narouie
Abstract
Prostate cancer is one of the leading causes of cancer-related deaths among men worldwide. Research has shown that genetic variations can increase an individual's risk of developing this disease. In this study, we investigated the potential role of two genetic variants, one within RFX6 and another within ...
Read More
Prostate cancer is one of the leading causes of cancer-related deaths among men worldwide. Research has shown that genetic variations can increase an individual's risk of developing this disease. In this study, we investigated the potential role of two genetic variants, one within RFX6 and another within SLC22A3, in predisposition to prostate cancer. A genetic association study was conducted, involving a case-control design with 112 prostate cancer cases and 95 individuals affected by benign prostatic hyperplasia who served as controls and had no history of cancer. The genotypes of the two variants, rs339331 in RFX6 and rs9364554 in SLC22A3, were determined using tetra-primer ARMS-PCR. In this study, a multi-stage strategy was employed to analyze the data obtained from genotyping and to assess the association of these two variants with prostate cancer risk. For statistical analysis, Chi-squared, Fisher’s exact test and logistic regression were performed to evaluate the association of variants with prostate cancer and Gleason score. The results suggest that the rs9364554 variant in SLC22A3 is not associated with prostate cancer risk under either additive or multiplicative genetic models, while the variant in RFX6 is significantly associated with prostate cancer susceptibility. The TT genotype of rs339331 indicated a possible protective effect against prostate adenocarcinoma (CI 95% = 0/009 -0/725, P-value = 0/009, OR = 0/083). In conclusion, our study provides evidence that the genetic variant rs339331 within RFX6 is significantly associated with prostate cancer susceptibility and may have a potential protective effect against prostate adenocarcinoma. It should be mentioned that more research is needed to investigate the possible protective effect of the TT genotype of rs9364554 against prostate cancer risk in other populations and various ethnic groups and particularly larger sample sizes are required to confirm this association.
